CancerIQ
United States
- Chicago, Illinois
- 04/03/2022
- Series B
- $14,000,000
About Us
CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.
Why Work with Us?
We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We've a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.
- Industry Hospital & Health Care
- Website https://www.canceriq.com/
- LinkedIn https://www.linkedin.com/company/cancer-iq-inc-/about/
Golden Analytics | $7,000,000 | (Apr 9, 2026)
HexemBio | $10,400,000 | (Apr 9, 2026)
E2 - Endovascular Engineering | $80,000,000 | (Apr 9, 2026)
True Footage | $40,000,000 | (Apr 9, 2026)
Petwealth | $1,700,000 | (Apr 9, 2026)
Pomo | $4,500,000 | (Apr 9, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
GoSats - The simplest onramp to Digital Assets in India | $5,000,000 | (Apr 9, 2026)
Life Biosciences | $80,000,000 | (Apr 9, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)